Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Our mission is to take a rare and uncommon approach and develop a platform that accelerates the discovery of therapeutic solutions for patients.

To be a leader in discovering and developing novel and innovative treatments for rare and serious neurological, pain and movement disorders and to become a trusted partner for those affected.

In 2018, Xenon was named to Deloitte's Technology Fast 50™ awards, Samumed's Technology Fast 500™ awards and the John M. Facey Award for Commercialization Excellence. In 2011, Xenon won the Ernst & Young Entrepreneur of the Year® award in Life Sciences.